|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rahib L, Smith BD, Aizenberg R, Rosenzweig
AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and
deaths to 2030: The unexpected burden of thyroid, liver, and
pancreas cancers in the United States. Cancer Res. 74:2913–2921.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kamisawa T, Wood LD, Itoi T and Takaori K:
Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lefebvre AC, Maurel J, Boutreux S, Bouvier
V, Reimund JM, Launoy G and Arsene D: Pancreatic cancer: Incidence
treatment and survival trends-1175 cases in Calvados (France) from
1978 to 2002. Gastroenterol Clin Biol. 33:1045–1051. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sant M, Allemani C, Santaquilani M, Knijn
A, Marchesi F and Capocaccia R; EUROCARE Working Group: EUROCARE-4:
Survival of cancer patients diagnosed in 1995-1999 Results and
commentary. Eur J Cancer. 45:931–991. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li HB, Zhou J and Zhao FQ: A prognostic
nomogram for disease-specific survival in patients with pancreatic
ductal adenocarcinoma of the head of the pancreas following
pancreatic-coduodenectomy. Med Sci Monit. 24:6313–6321. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ahrendt SA and Pitt HA: Surgical
management of pancreatic cancer. Oncology (Williston Park).
16:725–734. 2002.
|
|
8
|
Cecconi D, Palmieri M and Donadelli M:
Proteomics in pancreatic cancer research. Proteomics. 11:816–828.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang Gillam A, Li CP, Bodoky G, Dean A,
Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, et
al: Nanoliposomal irinotecan with fluorouracil and folinic acid in
metastatic pancreatic cancer after previous gemcitabine based
therapy (NAPOLI-1): A global, randomised, open-label, phase 3
trial. Lancet. 387:545–557. 2016. View Article : Google Scholar
|
|
12
|
Burris HA III, Moore MJ, Andersen J, Green
MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo
AM, Tarassoff P, et al: Improvements in survival and clinical
benefit with gemcitabine as first-line therapy for patients with
advanced pancreas cancer: A randomized trial. J Clin Oncol.
15:2403–2413. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kirchhoff C, Habben I, Ivell R and Krull
N: A major human epididymis-specific cDNA encodes a protein with
sequence homology to extracellular proteinase inhibitors. Biol
Reprod. 45:350–357. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kirchhoff C: Molecular characterization of
epididymal proteins. Rev Reprod. 3:86–95. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Clauss A, Lilja H and Lundwall A: A locus
on human chromosome 20 contains several genes expressing protease
inhibitor domains with homology to whey acidic protein. Biochem J.
368:233–242. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bingle CD: Towards defining the complement
of mammalian WFDC-domain-containing proteins. Biochem Soc Trans.
39:1393–1397. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Drapkin R, von Horsten HH, Lin Y, Mok SC,
Crum CP, Welch WR and Hecht JL: Human epididymis protein 4 (HE4) is
a secreted glycoprotein that is overexpressed by serous and
endometrioid ovarian carcinomas. Cancer Res. 65:2162–2169. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hellström I, Raycraft J, Hayden-Ledbetter
M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N and
Hellström KE: The HE4 (WFDC2) protein is a biomarker for ovarian
carcinoma. Cancer Res. 63:3695–3700. 2003.PubMed/NCBI
|
|
19
|
Trudel D, Têtu B, Grégoire J, Plante M,
Renaud MC, Bachvarov D, Douville P and Bairati I: Human epididymis
protein 4 (HE4) and ovarian cancer prognosis. Gynecol Oncol.
127:511–515. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bignotti E, Ragnoli M, Zanotti L, Calza S,
Falchetti M, Lonardi S, Bergamelli S, Bandiera E, Tassi RA, Romani
C, et al: Diagnostic and prognostic impact of serum HE4 detection
in endometrial carcinoma patients. Br J Cancer. 104:1418–1425.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li X, Gao Y, Tan M, Zhuang H, Gao J, Hu Z,
Wang H, Zhu L, Liu J and Lin B: Expression of HE4 in endometrial
cancer and its clinical significance. Biomed Res Int.
2015:4374682015.PubMed/NCBI
|
|
22
|
Iwahori K, Suzuki H, Kishi Y, Fujii Y,
Uehara R, Okamoto N, Kobayashi M, Hirashima T, Kawase I and Naka T:
Serum HE4 as a diagnostic and prognostic marker for lung cancer.
Tumour Biol. 33:1141–1149. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yamashita S, Tokuishi K, Hashimoto T,
Moroga T, Kamei M, Ono K, Miyawaki M, Takeno S, Chujo M, Yamamoto S
and Kawahara K: Prognostic significance of HE4 expression in
pulmonary adenocarcinoma. Tumour Biol. 32:265–271. 2011. View Article : Google Scholar
|
|
24
|
Zhong H, Qian Y, Fang S, Yang L, Li L and
Gu W: HE4 expression in lung cancer, a meta-analysis. Clin Chim
Acta. 470:109–114. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kamei M, Yamashita S, Tokuishi K, Hashioto
T, Moroga T, Suehiro S, Ono K, Miyawaki M, Takeno S, Yamamoto S and
Kawahara K: HE4 expression can be associated with lymph node
metastases and disease-free survival in breast cancer. Anticancer
Res. 30:4779–4783. 2010.PubMed/NCBI
|
|
26
|
Guo YD, Wang JH, Lu H, Li XN, Song WW,
Zhang XD and Zhang WM: The human epididymis protein 4 acts as a
prognostic factor and promotes progression of gastric cancer.
Tumour Biol. 36:2457–2464. 2015. View Article : Google Scholar :
|
|
27
|
Kemal YN, Demirag GN, Bedir AM, Tomak L,
Derebey M, Erdem DL, Gör U and Yücel I: Serum human epididymis
protein 4 levels in colorectal cancer patients. Mol Clin Oncol.
7:481–485. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Galgano MT, Hampton GM and Frierson HF Jr:
Comprehensive analysis of HE4 expression in normal and malignant
human tissues. Mod Pathol. 19:847–853. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jiang SW, Chen H, Dowdy S, Fu A, Attewell
J, Kalogera E, Drapkin R, Podratz K, Broaddus R and Li J: HE4
transcription- and splice variants-specific expression in
endometrial cancer and correlation with patient survival. Int J Mol
Sci. 14:22655–22677. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ryu B, Jones J, Blades NJ, Parmigiani G,
Hollingsworth MA, Hruban RH and Kern SE: Relationships and
differentially expressed genes among pancreatic cancers examined by
large-scale serial analysis of gene expression. Cancer Res.
62:819–826. 2002.PubMed/NCBI
|
|
31
|
O'Neal RL, Nam KT, LaFleur BJ, Barlow B,
Nozaki K, Lee HJ, Kim WH, Yang HK, Shi C, Maitra A, et al: Human
epididymis protein 4 is up-regulated in gastric and pancreatic
adenocarcinomas. Hum Pathol. 44:734–742. 2013. View Article : Google Scholar
|
|
32
|
Huang T, Jiang SW, Qin L, Senkowski C,
Lyle C, Terry K, Brower S, Chen H, Glasgow W, Wei Y and Li J:
Expression and diagnostic value of HE4 in pancreatic
adenocarcinoma. Int J Mol Sci. 16:2956–2970. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lu Q, Chen H, Senkowski C, Wang J, Wang X,
Brower S, Glasgow W, Byck D, Jiang SW and Li J: Recombinant HE4
protein promotes proliferation of pancreatic and endometrial cancer
cell lines. Oncol Rep. 35:163–170. 2016. View Article : Google Scholar
|
|
34
|
Ohkuma R, Yada E, Ishikawa S, Komura D,
Ishizaki H, Tamada K, Kubota Y, Hamada K, Ishida H, Hirasawa Y, et
al: High expression of olfactomedin-4 is correlated with
chemoresistance and poor prognosis in pancreatic cancer. PLoS One.
15:e02267072020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Morton CL and Houghton PJ: Establishment
of human tumor xenografts in immunodeficient mice. Nat Protoc.
2:247–250. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chijiwa T, Kawai K, Noguchi A, Sato H,
Hayashi A, Cho H, Shiozawa M, Kishida T, Morinaga S, Yokose T, et
al: Establishment of patient-derived cancer xenografts in
immune-deficient NOG mice. Int J Oncol. 47:61–70. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Langmead B, Trapnell C, Pop M and Salzberg
SL: Ultrafast and memory-efficient alignment of short DNA sequences
to the human genome. Genome Biol. 10:R252009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Komura D, Isagawa T, Kishi K, Suzuki R,
Sato R, Tanaka M, Katoh H, Yamamoto S, Tatsuno K, Fukayama M, et
al: CASTIN: A system for comprehensive analysis of cancer stromal
interactome. BMC Genomics. 17:8992016. View Article : Google Scholar
|
|
39
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expres sion data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
40
|
Jin K, Li G, Cui B, Zhang J, Lan H, Han N,
Xie B, Cao F, He K, Wang H, et al: Assessment of a novel VEGF
targeted agent using patient-derived tumor tissue xenograft models
of colon carcinoma with lymphatic and hepatic metastases. PLoS One.
6:e283842011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yada E, Wada S, Yoshida S and Sanada T:
Use of patient-derived xenograft mouse models in cancer research
and treatment. Future Sci OA. 4:FSO2712017. View Article : Google Scholar
|
|
42
|
Hidalgo M, Amant F, Biankin AV, Budinská
E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo
GM, et al: Patient derived xenograft models: An emerging platform
for translational cancer research. Cancer Discov. 4:998–1013. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cho SY, Kang W, Han JY, Min S, Kang J, Lee
A, Kwon JY, Lee C and Park H: An integrative approach to precision
cancer medi cine using patient-derived xenografts. Mol Cells.
39:77–86. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lefford H: US Cancer Institute to overhaul
tumour cell lines. Nature. 530:3912016. View Article : Google Scholar
|
|
45
|
Fujii E, Suzuki M, Matsubara K, Watanabe
M, Chen YJ, Adachi K, Ohnishi Y, Tanigawa M, Tsuchiya M and Tamaoki
N: Establishment and characterization of in vivo human tumor models
in the NOD/SCID/gamma(c)(null) mouse. Pathol Int. 58:559–567. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Galimi F, Torti D, Sassi F, Isella C, Corà
D, Gastaldi S, Ribero D, Muratore A, Massucco P, Siatis D, et al:
Genetic and expression analysis of MET, MACC1, and HGF in
metastatic colorectal cancer: Response to met inhibition in patient
xenografts and pathologic correlations. Clin Cancer Res.
17:3146–3156. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bertotti A, Migliardi G, Galimi F, Sassi
F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti
C, et al: A molecularly annotated platform of patient-derived
xenografts ('xenopatients') identifies HER2 as an effective
therapeutic target in cetuximab-resistant colorectal cancer. Cancer
Discov. 1:508–523. 2011. View Article : Google Scholar
|
|
48
|
de Sousa Abreu R, Penalva LO, Marcotte EM
and Vogel C: Global signatures of protein and mRNA expression
levels. Mol Biosyst. 5:1512–1526. 2009.PubMed/NCBI
|
|
49
|
Schwanhäusser B, Busse D, Li N, Dittmar G,
Schuchhardt J, Wolf J, Chen W and Selbach M: Global quantification
of mammalian gene expression control. Nature. 473:337–342. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wu L, Candille SI, Choi Y, Xie D, Jiang L,
Li-Pook-Than J, Tang H and Snyder M: Variation and genetic control
of protein abundance in humans. Nature. 499:79–82. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhang B, Wang J, Wang X, Zhu J, Liu Q, Shi
Z, Chambers MC, Zimmerman LJ, Shaddox KF, Kim S, et al:
Proteogenomic characterization of human colon and rectal cancer.
Nature. 513:382–387. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zou SL, Chang XH, Ye X, Cheng HY, Cheng
YX, Tang ZJ, Zhang ZJ, Gao L, Chen XH and Cui H: Effect of human
epididymis protein 4 gene silencing on the malignant phenotype in
ovarian cancer. Chin Med J (Engl). 124:3133–3140. 2011.
|
|
53
|
Zhu YF, Gao GL, Tang SB, Zhang ZD and
Huang QS: Effect of WFDC 2 silencing on the proliferation, motility
and invasion of human serous ovarian cancer cells in vitro. Asian
Pac J Trop Med. 6:265–272. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhuang H, Hu Z, Tan M, Zhu L, Liu J, Liu
D, Yan L and Lin B: Overexpression of Lewis yantigen promotes human
epididymis protein 4-mediated invasion and metastasis of ovarian
cancer cells. Biochimie. 105:91–98. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lu R, Sun X, Xiao R, Zhou L, Gao X and Guo
L: Human epididymis protein 4 (HE4) plays a key role in ovarian
cancer cell adhesion and motility. Biochem Biophys Res Commun.
419:274–280. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Li J, Chen H, Mariani A, Chen D, Klatt E,
Podratz K, Drapkin R, Broaddus R, Dowdy S and Jiang SW: HE4 (WFDC2)
promotes tumor growth in endometrial cancer cell lines. Int J Mol
Sci. 14:6026–6043. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Lee S, Choi S, Lee Y, Chung D, Hong S and
Park N: Role of human epididymis protein 4 in chemoresistance and
prognosis of epithelial ovarian cancer. J Obstet Gynaecol Res.
43:220–227. 2017. View Article : Google Scholar
|
|
58
|
Moore RG, Hill EK, Horan T, Yano N, Kim K,
MacLaughlan S, Lambert-Messerlian G, Tseng YD, Padbury JF, Miller
MC, et al: HE4 (WFDC2) gene overexpression promotes ovarian tumor
growth. Sci Rep. 4:35742014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Maihle NJ, Baron AT, Barrette BA, Boardman
CH, Christensen TA, Cora EM, Faupel-Badger JM, Greenwood T, Juneja
SC, Lafky JM, et al: EGF/ErbB receptor family in ovarian cancer.
Cancer Treat Res. 107:247–258. 2002.PubMed/NCBI
|
|
60
|
Gotlieb WH, Bruchim I, Gu J, Shi Y,
Camirand A, Blouin MJ, Zhao Y and Pollak MN: Insulin-like growth
factor receptor I targeting in epithelial ovarian cancer. Gynecol
Oncol. 100:389–396. 2006. View Article : Google Scholar
|
|
61
|
Spannuth WA, Nick AM, Jennings NB,
Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker
PH, Kamat AA, et al: Functional significance of VEGFR-2 on ovarian
cancer cells. Int J Cancer. 124:1045–1053. 2009. View Article : Google Scholar :
|
|
62
|
Braicu EI, Fotopoulou C, Van Gorp T,
Richter R, Chekerov R, Hall C, Butz H, Castillo-Tong DC, Mahner S,
Zeillinger R, et al: Preoperative HE4 expression in plasma predicts
surgical outcome in primary ovarian cancer patients: Results from
the OVCAD study. Gynecol Oncol. 128:245–251. 2013. View Article : Google Scholar
|
|
63
|
Ribeiro JR, Schorl C, Yano N, Romano N,
Kim KK, Singh RK and Moore RG: HE4 promotes collateral resistance
to cisplatin and paclitaxel in ovarian cancer cells. J Ovarian Res.
9:282016. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Wang H, Zhu L, Gao J, Hu Z and Lin B:
Promotive role of recombinant HE4 protein in proliferation and
carboplatin resistance in ovarian cancer cells. Oncol Rep.
33:403–412. 2015. View Article : Google Scholar
|
|
65
|
Angioli R, Capriglione S, Aloisi A, Guzzo
F, Luvero D, Miranda A, Damiani P, Montera R, Terranova C and
Plotti F: Can HE4 predict platinum response during first-line
chemotherapy in ovarian cancer? Tumour Biol. 35:7009–7015. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Oweira H, Petrausch U, Helbling D, Schmidt
J, Mannhart M, Mehrabi A, Schöb O, Giryes A, Decker M and
Abdel-Rahman O: Prognostic value of site-specific metastases in
pancreatic adenocarcinoma: A Surveillance epidemiology and end
results database analysis. World J Gastroenterol. 23:1872–1880.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Nipp R, Tramontano AC, Kong CY,
Pandharipande P, Dowling EC, Schrag D and Hur C: Disparities in
cancer outcomes across age, sex, and race/ethnicity among patients
with pancreatic cancer. Cancer Med. 7:525–535. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Maisey NR, Norman AR, Hill A, Massey A,
Oates J and Cunningham D: CA19-9 as a prognostic factor in
inoperable pancreatic cancer: The implication for clinical trials.
Br J Cancer. 93:740–743. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Piciucchi M, Stigliano S, Archibugi L,
Zerboni G, Signoretti M, Barucca V, Valente R, Fave GD and Capurso
G: The neutrophil/lymphocyte ratio at diagnosis is significantly
associated with survival in metastatic pancreatic cancer patients.
Int J Mol Sci. 18:7302017. View Article : Google Scholar :
|
|
70
|
Luo J, Xiao L, Wu C, Zheng Y and Zhao N:
The incidence and survival rate of population-based pancreatic
cancer patients: Shanghai Cancer Registry 2004-2009. PLoS One.
8:e760522013. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Baine M, Sahak F, Lin C, Chakraborty S,
Lyden E and Batra SK: Marital status and survival in pancreatic
cancer patients: A SEER based analysis. PLoS One. 6:e210522011.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
David M, Lepage C, Jouve JL, Jooste V,
Chauvenet M, Faivre J and Bouvier AM: Management and prognosis of
pancreatic cancer over a 30-year period. Br J Cancer. 101:215–218.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Liu X, Fu Y, Chen Q, Wu J, Gao W, Jiang K,
Miao Y and Wei J: Predictors of distant metastasis on exploration
in patients with potentially resectable pancreatic cancer. BMC
Gastroenterol. 18:1682018. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Hohla F, Hopfinger G, Romeder F,
Rinnerthaler G, Bezan A, Stättner S, Hauser-Kronberger C, Ulmer H
and Greil R: Female gender may predict response to FOLFIRINOX in
patients with unresectable pancreatic cancer: A single institution
retrospective review. Int J Oncol. 44:319–326. 2014. View Article : Google Scholar
|
|
75
|
Lambert A, Jarlier M, Gourgou Bourgade S
and Conroy T: Response to FOLFIRINOX by gender in patients with
metastatic pancreatic cancer: Results from the PRODIGE 4/ACCORD 11
randomized trial. PLoS One. 12:e01832882017. View Article : Google Scholar
|
